HK1258018A1 - Fgfr4抑制劑、其製備方法和應用 - Google Patents
Fgfr4抑制劑、其製備方法和應用Info
- Publication number
- HK1258018A1 HK1258018A1 HK19100388.9A HK19100388A HK1258018A1 HK 1258018 A1 HK1258018 A1 HK 1258018A1 HK 19100388 A HK19100388 A HK 19100388A HK 1258018 A1 HK1258018 A1 HK 1258018A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- applications
- preparation
- method therefor
- fgfr4 inhibitor
- fgfr4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610339009 | 2016-05-20 | ||
CN201611166598 | 2016-12-16 | ||
PCT/CN2017/084564 WO2017198149A1 (zh) | 2016-05-20 | 2017-05-16 | Fgfr4抑制剂、其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1258018A1 true HK1258018A1 (zh) | 2019-11-01 |
Family
ID=60326215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK19100388.9A HK1258018A1 (zh) | 2016-05-20 | 2019-01-10 | Fgfr4抑制劑、其製備方法和應用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11667631B2 (zh) |
EP (1) | EP3444250A4 (zh) |
JP (1) | JP7103952B2 (zh) |
CN (3) | CN109071532B (zh) |
HK (1) | HK1258018A1 (zh) |
TW (1) | TWI751163B (zh) |
WO (1) | WO2017198149A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2715708C2 (ru) | 2013-10-18 | 2020-03-03 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Ингибиторы fgfr4 |
SG10201810057UA (en) | 2015-04-14 | 2018-12-28 | Eisai R&D Man Co Ltd | Crystalline fgfr4 inhibitor compound and uses thereof |
JP7372740B2 (ja) | 2016-05-10 | 2023-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ |
KR102499780B1 (ko) | 2016-05-27 | 2023-02-16 | 항저우 인노게이트 파마 컴퍼니 리미티드 | Fgfr4 저해제인 헤테로 고리 화합물 |
US11608332B2 (en) * | 2016-08-12 | 2023-03-21 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | FGFR4 inhibitor and preparation method and use thereof |
CN110225913B (zh) * | 2017-10-31 | 2021-10-15 | 江苏豪森药业集团有限公司 | Fgfr4抑制剂晶型及其制备方法 |
CN110234649B (zh) * | 2017-10-31 | 2021-10-15 | 江苏豪森药业集团有限公司 | Fgfr4抑制剂的盐、晶体、制备方法及其用途 |
CN109745321B (zh) * | 2017-11-08 | 2022-04-29 | 上海翰森生物医药科技有限公司 | 包含fgfr4抑制剂的药物组合物 |
CN110240598B (zh) * | 2018-03-09 | 2023-07-25 | 上海翰森生物医药科技有限公司 | 甲酰胺衍生物的制备方法及其中间体化合物 |
TWI723480B (zh) | 2018-07-27 | 2021-04-01 | 大陸商北京加科思新藥研發有限公司 | 用作fgfr4抑制劑的稠環衍生物 |
CN111662285B (zh) * | 2019-03-07 | 2023-05-16 | 江苏豪森药业集团有限公司 | 2-氧代-1,3-氧杂氮杂环庚衍生物的制备方法 |
AU2020298246A1 (en) * | 2019-06-21 | 2022-01-27 | Terns Pharmaceuticals Inc. | Compounds for inhibiting FGFR4 |
CN113072550B (zh) * | 2020-01-06 | 2023-08-08 | 周龙兴 | 一种高选择性成纤维细胞生长因子受体抑制剂和应用 |
WO2022089648A1 (en) * | 2020-11-02 | 2022-05-05 | Jacobio Pharmaceuticals Co., Ltd. | Crystalline forms of salts of fgfr4 inhibitor |
WO2023207944A1 (zh) * | 2022-04-26 | 2023-11-02 | 石药集团中奇制药技术(石家庄)有限公司 | Fgfr4抑制剂的晶型及应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA028819B1 (ru) * | 2013-10-25 | 2018-01-31 | Новартис Аг | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 |
EP3200786B1 (en) * | 2014-10-03 | 2019-08-28 | Novartis AG | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
WO2016151501A1 (en) * | 2015-03-25 | 2016-09-29 | Novartis Ag | Pharmaceutical combinations |
US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
KR102499780B1 (ko) * | 2016-05-27 | 2023-02-16 | 항저우 인노게이트 파마 컴퍼니 리미티드 | Fgfr4 저해제인 헤테로 고리 화합물 |
-
2017
- 2017-05-16 CN CN201780013978.3A patent/CN109071532B/zh active Active
- 2017-05-16 EP EP17798712.0A patent/EP3444250A4/en active Pending
- 2017-05-16 JP JP2018560797A patent/JP7103952B2/ja active Active
- 2017-05-16 US US16/302,374 patent/US11667631B2/en active Active
- 2017-05-16 WO PCT/CN2017/084564 patent/WO2017198149A1/zh active Application Filing
- 2017-05-16 CN CN202110435282.8A patent/CN113105454B/zh active Active
- 2017-05-16 CN CN202110442076.XA patent/CN113234072B/zh active Active
- 2017-05-19 TW TW106116669A patent/TWI751163B/zh active
-
2019
- 2019-01-10 HK HK19100388.9A patent/HK1258018A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN109071532B (zh) | 2021-04-27 |
CN113105454B (zh) | 2022-10-11 |
TW201741311A (zh) | 2017-12-01 |
JP7103952B2 (ja) | 2022-07-20 |
WO2017198149A1 (zh) | 2017-11-23 |
CN113234072B (zh) | 2022-11-04 |
US20190276451A1 (en) | 2019-09-12 |
CN113234072A (zh) | 2021-08-10 |
JP2019519513A (ja) | 2019-07-11 |
TWI751163B (zh) | 2022-01-01 |
EP3444250A1 (en) | 2019-02-20 |
CN109071532A (zh) | 2018-12-21 |
EP3444250A4 (en) | 2019-09-25 |
CN113105454A (zh) | 2021-07-13 |
US11667631B2 (en) | 2023-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1258018A1 (zh) | Fgfr4抑制劑、其製備方法和應用 | |
ZA201701465B (en) | Egfr inhibitor, and preparation and application thereof | |
IL250588B (en) | Metrological method, purpose and substrate | |
EP3524603A4 (en) | FGFR4 INHIBITOR, PRODUCTION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | |
IL246597A0 (en) | Systems Spectrometric Methods and Applications | |
GB201512203D0 (en) | Agents,uses and methods | |
GB201522315D0 (en) | Securing webpages, webapps and applications | |
TWI800489B (zh) | Fgfr4抑制劑及其製備方法和應用 | |
IL252430A0 (en) | Antibodies, uses and methods | |
GB201516801D0 (en) | Method, array and use thereof | |
EP3307702A4 (en) | CHEMICAL P62 ZZ HEMMER | |
SG11202007554TA (en) | Dioxazoline compound, preparation method therefor, and uses thereof | |
EP3222625A4 (en) | Metal complex and light-emitting element using same | |
EP3244262A4 (en) | Radiation-sensitive composition and pattern forming method | |
IL280370A (en) | Metrological method, purpose and substrate | |
GB201512215D0 (en) | Agents,uses and methods | |
PL3429977T3 (pl) | Płyta kartonowo-gipsowa, sposób jej wytwarzania i jej zastosowanie | |
EP3381919A4 (en) | Substituted triazolopiperazine parp inhibitor, preparation method therefor, and use thereof | |
GB201503776D0 (en) | Compound and method | |
EP3232755A4 (en) | Component housing member, and component housing method | |
ZA201903845B (en) | Fgfr4 inhibitor and preparation method and use thereof | |
EP3359151A4 (en) | CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF | |
EP3121182A4 (en) | Metal complex and light-emitting element using same | |
EP3133069A4 (en) | Bcr-abl diploid inhibitor, preparation method therefor, and uses thereof | |
EP3239168A4 (en) | Conotoxin peptide -cptx-btl02, preparation method therefor, and uses thereof |